EMMA Stock Overview
A commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Emmaus Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.008 |
| 52 Week High | US$0.13 |
| 52 Week Low | US$0.0001 |
| Beta | 6.49 |
| 1 Month Change | -70.48% |
| 3 Month Change | -60.30% |
| 1 Year Change | -93.32% |
| 3 Year Change | -99.50% |
| 5 Year Change | -99.59% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMMA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -38.2% | 0.6% | -0.4% |
| 1Y | -93.3% | 10.0% | 24.8% |
Return vs Industry: EMMA underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: EMMA underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| EMMA volatility | |
|---|---|
| EMMA Average Weekly Movement | 89.9% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EMMA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EMMA's weekly volatility has decreased from 259% to 90% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 53 | Willis Lee | www.emmausmedical.com |
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell disease; ELS004, a pharmaceutical grade L-glutamine which has completed phase 1 clinical study to treat diverticulosis; ELS005 in preclinical study for the use and combination of KM10544 to treat blood cancers; ELS003, a lab device/research tool in preclinical study to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis is in preclinical study.
Emmaus Life Sciences, Inc. Fundamentals Summary
| EMMA fundamental statistics | |
|---|---|
| Market cap | US$890.92k |
| Earnings (TTM) | -US$3.50m |
| Revenue (TTM) | US$20.43m |
0.0x
P/S Ratio-0.1x
P/E RatioIs EMMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMMA income statement (TTM) | |
|---|---|
| Revenue | US$20.43m |
| Cost of Revenue | US$1.08m |
| Gross Profit | US$19.35m |
| Other Expenses | US$22.84m |
| Earnings | -US$3.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.055 |
| Gross Margin | 94.70% |
| Net Profit Margin | -17.11% |
| Debt/Equity Ratio | -54.2% |
How did EMMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 14:17 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Emmaus Life Sciences, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bradley Sorensen | Zacks Small-Cap Research |